Mark Bower

20.1k total citations · 1 hit paper
340 papers, 11.3k citations indexed

About

Mark Bower is a scholar working on Oncology, Pathology and Forensic Medicine and Epidemiology. According to data from OpenAlex, Mark Bower has authored 340 papers receiving a total of 11.3k indexed citations (citations by other indexed papers that have themselves been cited), including 206 papers in Oncology, 104 papers in Pathology and Forensic Medicine and 74 papers in Epidemiology. Recurrent topics in Mark Bower's work include Viral-associated cancers and disorders (169 papers), Lymphoma Diagnosis and Treatment (100 papers) and HIV/AIDS drug development and treatment (45 papers). Mark Bower is often cited by papers focused on Viral-associated cancers and disorders (169 papers), Lymphoma Diagnosis and Treatment (100 papers) and HIV/AIDS drug development and treatment (45 papers). Mark Bower collaborates with scholars based in United Kingdom, United States and Italy. Mark Bower's co-authors include Mark Nelson, Justin Stebbing, Brian Gazzard, Sundhiya Mandalia, E.S. Newlands, Tom Powles, Gordon Rustin, Tom Newsom‐Davis, L. Holden and Ashita Waterston and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Mark Bower

330 papers receiving 11.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Kaposi sarcoma

2019 402 citations Blossom Damania, Mark Bower et al. Nature Reviews Disease Primers profile →

Peers

Countries citing papers authored by Mark Bower

Since Specialization

Citations

This map shows the geographic impact of Mark Bower's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Bower with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Bower more than expected).

Fields of papers citing papers by Mark Bower

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Bower. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Bower. The network helps show where Mark Bower may publish in the future.

Co-authorship network of co-authors of Mark Bower

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Bower. A scholar is included among the top collaborators of Mark Bower based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Bower. Mark Bower is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Hepatocellular carcinoma in people living with HIV 2025 ·Journal of Hepatology ·Claudia Angela Maria Fulgenzi, Alessia Dalla Pria, Alberto Giovanni Leone, Ciro Celsa, Giuseppe Cabibbo, (unknown), Matthias Pinter, Antonio D’Alessio, (unknown), Norbert Bräu, Mark Bower, David J. Pinato	0
2	Management of KSHV/HHV8-Positive Multicentric Castleman Disease Concurrent With Other KSHV/HHV8-Positive Disorders: An Emergent Challenge in PLWH 2025 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Antonino Carbone, (unknown), Annunziata Gloghini, (unknown), Mark Bower	0
3	Clinical management of human herpesvirus-8-related illnesses in solid organ transplant recipients 2025 ·Journal of Infection ·Alessia Dalla Pria, Ines Ushiro‐Lumb, Mark Bower	3
4	Immune deficiency/dysregulation -associated lymphoproliferative disorders. Revised classification and management 2024 ·Blood Reviews ·Antonino Carbone, Amy Chadburn, Annunziata Gloghini, (unknown), Mark Bower	4
5	UK Cancer and Transition Service (UCATS): Providing tailored cancer care to the gender-diverse community. 2024 ·Journal of Clinical Oncology ·Alison Berner, (unknown), (unknown), Mark Bower	1
6	Taxonomic reclassification of Kaposi Sarcoma identifies disease entities with distinct immunopathogenesis 2023 ·Journal of Translational Medicine ·Mark R. Openshaw, (unknown), (unknown), David J. Pinato, Alessia Dalla Pria, Mark Bower	2
7	Natural immunity to SARS-CoV-2 and breakthrough infections in vaccinated and unvaccinated patients with cancer 2022 ·British Journal of Cancer ·Alessio Cortellini, Ramón Salazar, Mark Bower, Ailsa Sita-Lumsden, Andrea Plaja, Alvin Lee, Alexia Bertuzzi, Carlo Tondini, Nikolaos Diamantis, Clara Martínez-Vila, Aleix Prat, (unknown), Alessandra Gennari, David J. Pinato	5
8	Castleman disease 2021 ·Nature Reviews Disease Primers ·Antonino Carbone, Margaret Borok, Blossom Damania, Annunziata Gloghini, Mark N. Polizzotto, (unknown), David C. Fajgenbaum, Mark Bower	96
9	Outcomes of men with HIV and germ cell cancer: Results from an international collaborative study 2021 ·Cancer ·Marcus Hentrich, Mark Bower, Gedske Daugaard, Annette Dieing, Markus Bickel, Massimiliano Berretta, (unknown), Vindi Jurinović, Albrecht Stoehr, Julia Heinzelbecker, Ivanka Krznaric, Klaus‐Peter Dieckmann, Andrea Necchi, (unknown), Jürgen K. Rockstroh, (unknown), David Pfister, Christian Hoffmann	2
10	Oncogenic Herpesvirus Engages Endothelial Transcription Factors SOX18 and PROX1 to Increase Viral Genome Copies and Virus Production 2020 ·Cancer Research ·Silvia Gramolelli, (unknown), (unknown), (unknown), Thomas Günther, (unknown), Seppo Kaijalainen, Raquel Díaz, Adam Grundhoff, Caj Haglund, Joseph M. Ziegelbauer, Teijo Pellinen, Mark Bower, Mathias François, Päivi M. Ojala	16
11	Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment 2016 ·BMJ Open ·Andrew Hill, Dzintars Gotham, Joseph Fortunak, (unknown), (unknown), Manuel de Mora Martín, Haitham Shoman, Jacob Levi, William G. Powderly, Mark Bower	46
12	Short Communication: NKG2C ⁺ NK Cells Contribute to Increases in CD16 ⁺ CD56 ⁻ Cells in HIV Type 1 ⁺ Individuals with High Plasma Viral Load 2012 ·AIDS Research and Human Retroviruses ·John Gregson, Leticia Kuri-Cervantes, Christopher M. Mela, Brian Gazzard, Mark Bower, Martin R. Goodier	15
13	Lymphoma in the immunocompromised 2010 ·British Journal of Hospital Medicine ·Ailsa Sita-Lumsden, (unknown), Mark Bower	2
14	Highly Active Antiretroviral Therapy and the Incidence of Non–AIDS-Defining Cancers in People With HIV Infection 2008 ·Journal of Clinical Oncology ·Thomas Powles, David Robinson, Justin Stebbing, Jonathan Shamash, Mark Nelson, Brian Gazzard, (unknown), Henrik Møller, Mark Bower	269
15	Insights into the molecular biology and sero-epidemiology of Kaposiʼs sarcoma 2003 ·Current Opinion in Infectious Diseases ·Justin Stebbing, Simon Portsmouth, Mark Bower	24
16	HAART PROLONGS TIME TO TREATMENT FAILURE (TTF) IN KAPOSI'S SARCOMA (KS). 1999 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Mark Bower, (unknown), Kate Fife, (unknown), Mark Nelson, Brian Gazzard	11
17	Phase I trial of temozolomide using an extended continuous oral schedule. 1998 ·PubMed ·C. Brock, E.S. Newlands, Stephen R. Wedge, Mark Bower, Helen Evans, Iain Colquhoun, Mary E. Roddie, M.G. Glaser, (unknown), Gordon Rustin	228
18	Human trithorax gene rearrangements in therapy-related acute leukaemia after etoposide treatment. 1994 ·PubMed ·Mark Bower, Pauline Parry, Barbara Gibbons, J. Amess, (unknown), BD Young, (unknown)	18
19	A Quadratic Distance Classifier for Multi-Class SAR ATR using Correlation Filters. 1993 ·Proc SPIE ·Abhijit Mahalanobis, (unknown), Mark Bower, (unknown), (unknown)	6
20	The use of nasal calcitonin spray in the treatment of hypercalcaemia of malignancy 1991 ·Cancer Chemotherapy and Pharmacology ·Mark Bower, Robert C. Stein, (unknown), (unknown), Kay W. Colston, R. Charles Coombes	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact